Clinical Trials Logo

Dyskinesias clinical trials

View clinical trials related to Dyskinesias.

Filter by:

NCT ID: NCT03354455 Completed - Parkinson Disease Clinical Trials

Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Using a within‐subject cross‐over design, we will include 20 patients with Parkinson disease (PD) and peak‐of‐dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication. On two separate days, each patient will receive off‐line, effective (high‐intensity) or ineffective (low‐intensity) 1 Hz repetitive transcranial magnetic stimulation (rTMS) of the presupplementary motor area (preSMA) before functional magnetic resonance (fMRI). Immediately after the patient will perform a Go/No-Go task during fMRI in the the OFF state for 9 minutes. Then the scan is paused and the patient will receive 200 mg fast‐acting oral levodopa and undergo whole‐brain task‐related fMRI at 3 Tesla until peak‐of‐dose dyskinesia will emerge. During task‐related fMRI, patients has to click on a mouse with their right hand (Right‐Go), left hand (Left‐Go), or no action (No‐Go) in response to arbitrary visual cues. The patients will also be tested for different aspects of impulsivity using neuropsychological questionnaires and computerized tests.

NCT ID: NCT03331848 Withdrawn - Parkinson Disease Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

ATTUNED
Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy

NCT ID: NCT03320382 Recruiting - Asthma Clinical Trials

Multiple Breath Washout, a Clinimetric Dataset

Start date: May 5, 2017
Phase:
Study type: Observational

Monitoring patients with chronic, inflammatory airways disease particularly in the early stages is hampered by the relative insensitivity of current outcome measures to detect subtle changes. Multiple breath washout is a potential sensitive test that is a useful readout of disease at these early stages but it lacks standardisation and knowledge of variability with reference to standard lung function measures. This is a Cross sectional and longitudinal observation study. The hypothesis is that multiple breath washout-derived indices will provide a robust signal of gas mixing inhomogeneity, correlating with conventional measures of airway disease severity. Multiple breath washout performed on different devices will generate indices which correlate but differ in value.

NCT ID: NCT03319485 Active, not recruiting - Parkinson Disease Clinical Trials

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

Start date: February 9, 2018
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.

NCT ID: NCT03287778 Completed - Tardive Dyskinesia Clinical Trials

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist. This study will test the efficacy of pyridoxine (also known as vitamin B6) for TD. This will be an 8 week double-blind, placebo-controlled, randomized trial measuring the effect of pyridoxine 400 mg/day on the severity of involuntary muscle movements in people who meet Schooler-Kane criteria for TD. Participants: Approximately 50 subjects will be recruited from the UNC Schizophrenia Treatment and Evaluation Program (STEP) and other local psychiatric clinics. Procedures (methods): Symptoms of TD will be assessed using the Abnormal Involuntary Movement Scale (AIMS). Pharmacological Intervention: All participants who meet entry criteria will be randomized to one of two treatment groups: pyridoxine or placebo.

NCT ID: NCT03279965 Recruiting - Cystic Fibrosis Clinical Trials

MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia

Start date: May 5, 2017
Phase: N/A
Study type: Observational

This is a small pilot / feasibility study (Approximately 50 patients) to assess the possibility of clinical implementation of MRI assessment of patients with cystic fibrosis and primary ciliary dyskinesia. Patients will undergo their standard CT imaging and lung function investigations and additionally will undergo MRI examination. Reports from CT (the current gold standard) and MRI will be assessed for concordance and patient acceptability and examination implementation costs will also be assessed. Novel MRI-based potential markers of CF and PCD disease state will also be assessed.

NCT ID: NCT03277950 Not yet recruiting - Stroke Clinical Trials

Effect of Virtual Reality Game on Upper Limb Movement in Individuals With Stroke

VRULS
Start date: September 15, 2017
Phase: N/A
Study type: Interventional

Individuals with stroke show abnormal movement pattern of upper limb. The movement pattern needs to be corrected. There are several methods to train normal movement. Exercise with technology is an active movement and affects sensory and cognitive systems. It may benefit to individuals with stroke in training.

NCT ID: NCT03271840 Completed - Clinical trials for Primary Ciliary Dyskinesia

Registry for Primary Ciliary Dyskinesia

Start date: August 26, 2017
Phase:
Study type: Observational [Patient Registry]

Primary Ciliary Dyskinesia (PCD) is a rare disease, which means that any single PCD center has experience with a limited number of patients. PCD Registry is the collection of data about PCD from many centers and countries who treat children with PCD. Collecting data about PCD increase the knowledge on PCD, better describe the course of the disease, and help to better understand the progression of the disease and be used to develop new treatments. In the PCD registry of Alberta, important information about PCD such as time of diagnosis, symptoms, and tests which led to the diagnosis, state of health at diagnosis, the progression of lung function, the occurrence of severe infections, tests and treatments data will be collected from the patients' medical records.

NCT ID: NCT03270189 Terminated - Clinical trials for Nervous System Diseases

Effect of the Visual Information Change in Functional Dystonia

PRISMADYS
Start date: September 18, 2017
Phase: N/A
Study type: Interventional

Cervical dystonia occurring only during the writing task is a rare form for which there is no established treatment. Many authors agree that alteration of sensory integration is associated with dystonia. Similar disturbances in the integration of oculomotor information could have a role in cervical dystonia forms involving visuo-cervico-manual coordination such as handwriting. We hypothesize that orthoptic treatment by wearing prisms when writing (i) will reduce the abnormal posture of the head occurring whilst writing and remove the associated nuchal pain; (ii) the correction after a period of systematic wearing of the prisms during handwriting tasks will have a sustainable effect allowing to keep a normal head position after the suppression of the prisms.

NCT ID: NCT03256773 Recruiting - Covid19 Clinical Trials

High Resolution Micro OCT Imaging

Start date: April 15, 2016
Phase:
Study type: Observational

The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.